1694 related articles for article (PubMed ID: 28725044)
1. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
[TBL] [Abstract][Full Text] [Related]
2. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
3. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
[TBL] [Abstract][Full Text] [Related]
4. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
5. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
Hoyos V; Savoldo B; Quintarelli C; Mahendravada A; Zhang M; Vera J; Heslop HE; Rooney CM; Brenner MK; Dotti G
Leukemia; 2010 Jun; 24(6):1160-70. PubMed ID: 20428207
[TBL] [Abstract][Full Text] [Related]
6. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
Quintarelli C; Sivori S; Caruso S; Carlomagno S; Falco M; Boffa I; Orlando D; Guercio M; Abbaszadeh Z; Sinibaldi M; Di Cecca S; Camera A; Cembrola B; Pitisci A; Andreani M; Vinti L; Gattari S; Del Bufalo F; Algeri M; Li Pira G; Moseley A; De Angelis B; Moretta L; Locatelli F
Leukemia; 2020 Apr; 34(4):1102-1115. PubMed ID: 31745215
[TBL] [Abstract][Full Text] [Related]
8. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
[TBL] [Abstract][Full Text] [Related]
9. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
Guo S; Lei W; Jin X; Liu H; Wang JQ; Deng W; Qian W
Blood Adv; 2024 Jun; 8(11):2635-2645. PubMed ID: 38564778
[TBL] [Abstract][Full Text] [Related]
10. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
11. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
12. High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
Abbaszade Dibavar M; Soleimani M; Mohammadi MH; Zomorrod MS
In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):321-332. PubMed ID: 38589736
[TBL] [Abstract][Full Text] [Related]
13. Human IL-15 Inhibits NK Cells Specific for Human NK-92 Cells.
Bergman H; Lindqvist C
Anticancer Res; 2021 Jul; 41(7):3281-3285. PubMed ID: 34230122
[TBL] [Abstract][Full Text] [Related]
14. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
Lin SJ; Kuo ML
Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
[TBL] [Abstract][Full Text] [Related]
16. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
17. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
Gang M; Marin ND; Wong P; Neal CC; Marsala L; Foster M; Schappe T; Meng W; Tran J; Schaettler M; Davila M; Gao F; Cashen AF; Bartlett NL; Mehta-Shah N; Kahl BS; Kim MY; Cooper ML; DiPersio JF; Berrien-Elliott MM; Fehniger TA
Blood; 2020 Nov; 136(20):2308-2318. PubMed ID: 32614951
[TBL] [Abstract][Full Text] [Related]
18. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
19. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
[TBL] [Abstract][Full Text] [Related]
20. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies.
Luanpitpong S; Poohadsuan J; Klaihmon P; Issaragrisil S
J Immunol Res; 2021; 2021():5562630. PubMed ID: 34337077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]